Publicacións en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (36)

2024

  1. Dispersal history of SARS-CoV-2 in Galicia, Spain

    Journal of Medical Virology, Vol. 96, Núm. 7

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Influence of Otolaryngological Subspecialties on Perception of Transoral Robotic Surgery: An International YO-IFOS Survey

    Journal of Personalized Medicine, Vol. 13, Núm. 12

  3. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  4. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2021

  1. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. High-flow nasal oxygen therapy in acute hypoxemic respiratory failure: Concise review on technology and initial methodology

    Turkish Thoracic Journal, Vol. 22, Núm. 6, pp. 494-500

  4. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

    Value in Health, Vol. 24, Núm. 11, pp. 1676-1685

2020

  1. Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36

    Neuron, Vol. 107, Núm. 2, pp. 292-305.e6

  2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769

2019

  1. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726

2017

  1. Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke

    Neuroradiology, Vol. 59, Núm. 4, pp. 343-351

  2. High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

    PLoS ONE, Vol. 12, Núm. 11

  3. Prevalence of spinocerebellar ataxia 36 in a US population

    Neurology: Genetics, Vol. 3, Núm. 4

2016

  1. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II

    European Heart Journal, Vol. 37, Núm. 33, pp. 2591-2601

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222